Abstract: A compound of general formula (III?), or one of its pharmaceutically acceptable salts, for its use for the treatment of hemophilia in a subject, in particular for the restoration of coagulation in the plasma of a subject suffering from hemophilia, this compound being advantageously administered by oral route:

Abstract: The present invention relates to a method for dynamically determining the structural profile of a fibrin clot, reflecting the stability thereof in a biological sample of a patient. The method preferably includes a step that makes it possible to predict the risk of bleeding, thrombosis or rethrombosis and to select the anticoagulant that is best suited to the clinical situation of a patient.

Abstract: A process for obtaining an adapted strain of Pseudomonas includes the following steps: deleting the genes ExoS, ExoT, aroA and lasl in an initial Pseudomonas strain cultivated in a LB medium; progressively cultivating this strain in a chemically defined medium based on a glucose minimal medium supplemented with magnesium and calcium; wherein the adapted strain presents the same toxicity and secretion capacities than the initial strain, and its doubling time when cultivated in the chemically defined medium is less than 60 minutes. An adapted strain is furthermore treated to become “killed but metabolically active.

Abstract: A process for obtaining an adapted strain of Pseudomonas includes the following steps: deleting the genes ExoS, ExoT, aroA and IasI in an initial Pseudomonas strain cultivated in a LB medium; progressively cultivating this strain in a chemically defined medium based on a glucose minimal medium supplemented with magnesium and calcium; wherein the adapted strain presents the same toxicity and secretion capacities than the initial strain, and its doubling time when cultivated in the chemically defined medium is less than 60 minutes. An adapted strain is furthermore treated to become ‘killed but metabolically active’.

Abstract: The present invention relates to a pharmaceutical composition including a modified factor Xa (GDXa), said modified GDXa being nonthrombogenic, able to bind to TFPI but not able to bind to phospholipids, for preventing or treating a hemorrhagic accident in a patient with hemophilia A or B with or without inhibitor.

Abstract: The present invention relates to a protein consisting of the sequence SEQ ID No.: 11 or 25 or 26, directly bound, or bound via a linker, especially -Arg-Lys-Arg-, to the sequence SEQ ID No.: 6.

Abstract: A process for obtaining an adapted strain of Pseudomonas includes the following steps: deleting the genes ExoS, ExoT, aroA and IasI in an initial Pseudomonas strain cultivated in a LB medium; progressively cultivating this strain in a chemically defined medium based on a glucose minimal medium supplemented with magnesium and calcium; wherein the adapted strain presents the same toxicity and secretion capacities than the initial strain, and its doubling time when cultivated in the chemically defined medium is less than 60 minutes. An adapted strain is furthermore treated to become ‘killed but metabolically active’.

Abstract: The present invention relates to a pharmaceutical composition including a modified factor Xa (GDXa), said modified GDXa being nonthrombogenic, able to bind to TFPI but not able to bind to phospholipids, for preventing or treating a hemorrhagic accident in a patient with hemophilia A or B with or without inhibitor.

Abstract: The present invention provides a vector for expression of a chimeric protein which is the result of the fusion between the N-terminal end of ExoS of Pseudomonas aeruginosa and an amino acid sequence of interest, the N-terminal end of ExoS corresponding to the N-terminal end of the chimeric protein. The vector contains the following from 5? to 3?: a promoter, a nucleic acid comprising a nucleotide sequence encoding at least the 48 (SEQ ID 4) and at the most the 96 (SEQ ID 6) amino acids of the N-terminal end of ExoS; or any sequence of the same size that is at least 70% identical thereto and that has a secretion activity at the same level as that of ExoS, a nucleic acid comprising a nucleotide sequence encoding the amino acid sequence of interest.

Abstract: The present invention provides a vector for expression of a chimeric protein which is the result of the fusion between the N-terminal end of ExoS of Pseudomonas aeruginosa and an amino acid sequence of interest, the N-terminal end of ExoS corresponding to the N-terminal end of the chimeric protein. The vector contains the following from 5? to 3?: a promoter, a nucleic acid comprising a nucleotide sequence encoding at least the 48 (SEQ ID 4) and at the most the 96 (SEQ ID 6) amino acids of the N-terminal end of ExoS; or any sequence of the same size that is at least 70% identical thereto and that has a secretion activity at the same level as that of ExoS, a nucleic acid comprising a nucleotide sequence encoding the amino acid sequence of interest.